These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 21223692)
1. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients]. Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117 [TBL] [Abstract][Full Text] [Related]
3. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728 [TBL] [Abstract][Full Text] [Related]
4. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860 [TBL] [Abstract][Full Text] [Related]
5. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients]. Hang ZQ; Zheng MF; Huang JH Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951 [TBL] [Abstract][Full Text] [Related]
6. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443 [TBL] [Abstract][Full Text] [Related]
7. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Muley T; Dienemann H; Ebert W Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383 [TBL] [Abstract][Full Text] [Related]
8. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967 [TBL] [Abstract][Full Text] [Related]
9. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited. Ma S; Shen L; Qian N; Chen K Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301 [TBL] [Abstract][Full Text] [Related]
10. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Yi Y; Li B; Wang Z; Sun H; Gong H; Zhang Z Biomarkers; 2009 Nov; 14(7):480-5. PubMed ID: 19863186 [TBL] [Abstract][Full Text] [Related]
11. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients]. Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892 [TBL] [Abstract][Full Text] [Related]
12. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer. Ando S; Kimura H; Iwai N; Yamamoto N; Iida T Anticancer Res; 2003; 23(3C):2869-74. PubMed ID: 12926125 [TBL] [Abstract][Full Text] [Related]
13. [Prognostic factors in patients with stage III and IV non-small cell lung cancer]. Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344 [TBL] [Abstract][Full Text] [Related]
14. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer. Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666 [TBL] [Abstract][Full Text] [Related]
15. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer]. Li R; Li R; Wang Y Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296 [TBL] [Abstract][Full Text] [Related]
16. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis]. Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326 [TBL] [Abstract][Full Text] [Related]
17. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer. Zhao T; Mao G; Chen M Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482 [TBL] [Abstract][Full Text] [Related]
18. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer. Jin B; Huang AM; Zhong RB; Han BH Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400 [TBL] [Abstract][Full Text] [Related]
19. Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression. Kanoh Y; Ohara T; Mashiko T; Abe T; Masuda N; Akahoshi T Anticancer Res; 2006; 26(6B):4293-7. PubMed ID: 17201147 [TBL] [Abstract][Full Text] [Related]
20. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer. Jiang AG; Chen HL; Lu HY BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]